Appointment dossier — Fallopian Tube Cancer

Compounds studied in Fallopian Tube Cancer

• Bevacizumab — Human evidence · 2 positive · PMID 38872480, 22529265
• Olaparib — Human evidence · 2 positive · PMID 37592269, 33743851
• Relacorilant — Human evidence · 2 positive / 1 negative-mixed · PMID 42334771, 40473448, 39032926, 37364223
• Mirvetuximab Soravtansine — Human evidence · 0 positive / 1 negative-mixed · PMID 30379722
• Nivolumab †Rx — Human evidence · 0 positive · PMID 34593565
• Rucaparib — Human evidence · 0 positive · PMID 34593565
• Carboplatin — Review evidence · 1 positive · PMID 37592269
• Fuzuloparib — Review evidence · 1 positive · PMID 34118019
• Paclitaxel — Review evidence · 1 positive / 1 negative-mixed · PMID 37592269, 10985612

“Positive” means a study reported a positive result — most are early lab/animal work that may not translate to people.

Open recruiting trials (18)

• NCT06824467 · Phase 3 — A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103) (United States)
• NCT07472140 · Phase 2 / Phase 3 — PARP (Poly (ADP-ribose) Polymerase) Inhibitor With or Without Angiogenesis Inhibitor in Homologous Recombination Deficient Primary Ovarian Cancer, Fallopian-Tube Cancer, or Primary Peritoneal Cancer (Belarus)
• NCT05009082 · Phase 3 — Niraparib vs Niraparib Plus Bevacizumab in Patients With Platinum/Taxane-based Chemotherapy in Advanced Ovarian Cancer (Germany)
• NCT05281471 · Phase 3 — Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076) (United States)
• NCT05086692 · Phase 1 / Phase 2 — A Beta-only IL-2 ImmunoTherapY Study (United States)
• NCT05377996 · Phase 1 / Phase 2 — A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors (United States)
• NCT06890338 · Phase 2 — A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer. (United States)
• NCT07023484 · Phase 2 — Personalized Timing of Interval Debulking Surgery in Advanced Ovarian Cancer (China)
• NCT07586826 · Phase 2 — Romiplostim N01 Plus ATRA for Persistent Isolated Chemotherapy-Induced Thrombocytopenia After Complete Remission of Gynecologic, Breast, or Lung Solid Tumors (China)
• NCT05200260 · Phase 2 — Surgery Combined With Maintenance Targeted Therapy in the Treatment of Advanced Ovarian Cancer (China)
• NCT05867251 · Phase 1 / Phase 2 — Study of AVZO-021 in Patients With Advanced Solid Tumors (United States)
• NCT04811703 · Phase 1 — Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) Associated With Systemic Chemotherapy in Women With Advanced Ovarian Cancer (France)
• NCT05429970 — A Study Comparing Perioperative Stress Reduction vs. Standard of Care in Ovarian Cancer (PRESERVE) (United States)
• NCT05287451 — Risk Reducing Salpingectomy With Delayed Oophorectomy as an Alternative to Risk- Reducing Salpingo-oophorectomy in High Risk-Women to Assess the Safety of Prevention - US Cohort Study (United States)
• NCT05503797 · Phase 2 — A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations (United States)
• NCT07213804 · Phase 3 — A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer (United States)
• NCT05737303 · Phase 3 — Nab-paclitaxel Versus Sb-taxanes As First-Line Treatment in Advanced Ovarian Cancer (China)
• NCT07285044 · Phase 2 — The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas (United States)

Most-relevant first: trials that name Fallopian Tube Cancer, then broader trials you may still qualify for. 118 recruiting trials name this cancer on ClinicalTrials.gov. Eligibility is decided by each trial's team — bring these NCT numbers to your appointment.

Interactions & safety to discuss

Not a complete check — a drug not listed here is not therefore safe. Show your pharmacist your full list.

• Nivolumab †Rx × immunosuppressants (high-stakes) — Avoid (high)
• Nivolumab †Rx × Ipilimumab — Synergize (moderate)
• Nivolumab †Rx × corticosteroids — Use For IrAE (low)

Financial help to look into

• PAN Foundation — Copay assistance funds by diagnosis (funds open and close as money allows). https://www.panfoundation.org/
• HealthWell Foundation — Copay and premium assistance funds by disease. https://www.healthwellfoundation.org/
• CancerCare — financial assistance — Limited grants plus free financial counseling. https://www.cancercare.org/financial
• Family Reach — Help with everyday living costs (rent, transport, food) during treatment. https://familyreach.org/
• NeedyMeds — Searchable directory of drug patient-assistance and discount programs. https://www.needymeds.org/

For each medicine above, search manufacturer and nonprofit programs at medicineassistancetool.org.

Questions to ask your oncologist

1. I've read that Bevacizumab has been studied in people for Fallopian Tube Cancer — what's the evidence, and is it an option or available in a trial for me?
2. I've read that Olaparib has been studied in people for Fallopian Tube Cancer — what's the evidence, and is it an option or available in a trial for me?
3. I've read that Relacorilant has been studied in people for Fallopian Tube Cancer — what's the evidence, and is it an option or available in a trial for me?
4. Of the open trials I found (for example NCT06824467), am I eligible for any — here or at a larger cancer center?
5. What is my exact diagnosis — the type, subtype, stage, and grade?
6. Has my tumor had molecular or genomic testing (e.g. next-generation sequencing), and what did it find?
7. Should I have inherited (germline) genetic testing, and could it affect my treatment or my family?
8. What is the goal of treatment for me — cure, long-term control, or comfort?
9. What are all of my standard treatment options, and what does each one involve?
10. What is the realistic benefit of each option, in actual numbers?
11. What are the most common and the most serious side effects, and how are they managed?
12. How will we know if treatment is working, and how often will I be scanned or tested?
13. If the first treatment doesn't work, what are the next options?
14. Are there gentler options if I want to prioritize quality of life?
15. Am I eligible for any clinical trials — here or at a larger/academic cancer center?
16. Is my case reviewed by a multidisciplinary tumor board?
17. Would a second opinion at a center that treats my cancer often be worthwhile?
18. Could any of my prescriptions, over-the-counter drugs, or supplements interfere with treatment?
19. Which symptoms are emergencies, and who do I call after hours?
20. Should I see palliative or supportive care alongside my treatment?
21. How will treatment affect my daily life, work, and (if it matters to me) fertility?
22. What can I safely do myself — diet and activity — and is anything I'm taking risky?